Matinas BioPharma has appointed a life sciences executive to its Board of Directors.
Eric J. Ende is a life sciences executive with over 20 years of financial leadership experience who currently serves as President of Ende BioMedical Consulting Group, which is focused on helping life sciences companies raise capital, and do better business, including analyzing private and public investment opportunities for clients within the life sciences industry. He also currently serves on the Technology Transfer Committee of Mount Sinai Innovation Partners.
Roelof Rongen, Chief Executive Officer of Matinas said that including Dr. Ende is important as the company is preparing to report clinical data in the near-term which has the potential to validate cochleate technology platform and prove to be transformative for Matinas. “His broad experience and proven track record in propelling companies to their next phase of growth will be integral as we continue to advance our corporate and clinical strategies,” said Rongen.
“There is a great need for transformational technologies to address a number of unmet needs in a range of multi-drug resistant infections. Matinas’ cochleate platform delivery technology has showcased its broad utility and ability to provide targeted delivery and reduce toxicity. I am excited to be joining the Company at such an exciting time and look forward to working with the management team and board to leverage this proprietary technology to provide much needed solutions for physicians and patients and unlock tremendous shareholder value,” commented Dr. Ende.